PDF herunterladen
Semin Liver Dis 2021; 41(01): 001-008
DOI: 10.1055/s-0040-1719178
Review Article

Role of Multidisciplinary Care in the Management of Hepatocellular Carcinoma

Kia Byrd
1   Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas
,
Saleh Alqahtani
2   Liver Transplantation Unit, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia
3   Department of Medicine, Johns Hopkins University, Baltimore, Maryland
,
Adam C. Yopp
4   Department of Surgery, UT Southwestern Medical Center, Dallas, Texas
,
Amit G. Singal
1   Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas
› Institutsangaben Funding Dr. Singal's research is supported in part by National Institutes of Health (NIH) R01 MD12565. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
› Weitere Informationen
   Lizenzen und Reprints

Abstract

Despite advances in treatment options for hepatocellular carcinoma (HCC), 5-year survival for HCC remains below 20%. This poor survival is multifactorial but is partly related to underuse of curative treatment in clinical practice. In light of growing treatment options, delivered by different types of providers, optimal management requires input from multiple specialties. A multidisciplinary approach has been evolving over the past couple of decades, bringing different specialists together to develop a therapeutic plan to treat and manage HCC, which significantly increases timely guideline-concordant treatment and improves overall survival. The present review attempts to highlight the need for such a multimodal approach by providing insights on its potential structure and impact on the various aspects of HCC management.

Keywords

liver cancer - treatment - multidisciplinary - guideline-concordant care - hepatocellular carcinoma


Publikationsverlauf

Artikel online veröffentlicht:
14. Januar 2021

© 2021. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 2019; S1542-3565(19)30849-3
    PubMedGoogle Scholar
  • 2 Yang JD, Kim WR, Coelho R. et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatol 2011; 9 (01) 64-70
    CrossrefPubMedGoogle Scholar
  • 3 Marrero JA, Kulik LM, Sirlin CB. et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018; 68 (02) 723-750
    Google Scholar
  • 4 Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014; 11 (04) e1001624
    CrossrefPubMedGoogle Scholar
  • 5 Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391 (10127): 1301-1314
    CrossrefPubMedGoogle Scholar
  • 6 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    CrossrefPubMedGoogle Scholar
  • 7 Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 2016; 36 (Suppl. 01) 124-129
    CrossrefPubMedGoogle Scholar
  • 8 Yao FY, Mehta N, Flemming J. et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015; 61 (06) 1968-1977
    Google Scholar
  • 9 Ishizawa T, Hasegawa K, Aoki T. et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology 2008; 134 (07) 1908-1916
    CrossrefPubMedGoogle Scholar
  • 10 Glantzounis GK, Tokidis E, Basourakos SP, Ntzani EE, Lianos GD, Pentheroudakis G. The role of portal vein embolization in the surgical management of primary hepatobiliary cancers. A systematic review. Eur J Surg Oncol 2017; 43 (01) 32-41
    CrossrefPubMedGoogle Scholar
  • 11 Gabr A, Polineni P, Mouli SK, Riaz A, Lewandowski RJ, Salem R. Neoadjuvant radiation lobectomy as an alternative to portal vein embolization in hepatocellular carcinoma. Semin Nucl Med 2019; 49 (03) 197-203
    CrossrefPubMedGoogle Scholar
  • 12 Kudo M, Ueshima K, Chan S. et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: a proof-of-concept study. Cancers (Basel) 2019; 11 (08) 11
    Google Scholar
  • 13 Dendy MS, Ludwig JM, Stein SM, Kim HS. Locoregional therapy, immunotherapy and the combination in hepatocellular carcinoma: future directions. Liver Cancer 2019; 8 (05) 326-340
    CrossrefPubMedGoogle Scholar
  • 14 Finn RS, Qin S, Ikeda M. IMbrave150 Investigators. et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
    CrossrefPubMedGoogle Scholar
  • 15 Fennell ML, Das IP, Clauser S, Petrelli N, Salner A. The organization of multidisciplinary care teams: modeling internal and external influences on cancer care quality. J Natl Cancer Inst Monogr 2010; 2010 (40) 72-80
    CrossrefPubMedGoogle Scholar
  • 16 Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2013; 38 (07) 703-712
    CrossrefPubMedGoogle Scholar
  • 17 Mokdad AA, Zhu H, Marrero JA, Mansour JC, Singal AG, Yopp AC. Hospital volume and survival after hepatocellular carcinoma diagnosis. Am J Gastroenterol 2016; 111 (07) 967-975
    CrossrefPubMedGoogle Scholar
  • 18 Singal AG, Waljee AK, Patel N. et al. Therapeutic delays lead to worse survival among patients with hepatocellular carcinoma. J Natl Compr Canc Netw 2013; 11 (09) 1101-1108
    CrossrefPubMedGoogle Scholar
  • 19 Hyder O, Dodson RM, Nathan H. et al. Referral patterns and treatment choices for patients with hepatocellular carcinoma: a United States population-based study. J Am Coll Surg 2013; 217 (05) 896-906
    CrossrefPubMedGoogle Scholar
  • 20 American College of Surgeons. Available at: https://www.facs.org/quality-programs/cancer/coc/standards/2020 2020. Accessed May 16, 2020
  • 21 Soukup T, Lamb BW, Arora S, Darzi A, Sevdalis N, Green JS. Successful strategies in implementing a multidisciplinary team working in the care of patients with cancer: an overview and synthesis of the available literature. J Multidiscip Healthc 2018; 11: 49-61
    CrossrefPubMedGoogle Scholar
  • 22 Elrashidi MY, Mohammed K, Bora PR. et al. Co-located specialty care within primary care practice settings: a systematic review and meta-analysis. Healthc (Amst) 2018; 6 (01) 52-66
    CrossrefPubMedGoogle Scholar
  • 23 Muñoz R, Farshidpour L, Chaudhary UB, Fathi AH. Multidisciplinary cancer care model: a positive association between oncology nurse navigation and improved outcomes for patients with cancer. Clin J Oncol Nurs 2018; 22 (05) E141-E145
    CrossrefPubMedGoogle Scholar
  • 24 Ferrante JM, Chen PH, Kim S. The effect of patient navigation on time to diagnosis, anxiety, and satisfaction in urban minority women with abnormal mammograms: a randomized controlled trial. J Urban Health 2008; 85 (01) 114-124
    CrossrefPubMedGoogle Scholar
  • 25 Elsayes KM, Kielar AZ, Chernyak V. et al. LI-RADS: a conceptual and historical review from its beginning to its recent integration into AASLD clinical practice guidance. J Hepatocell Carcinoma 2019; 6: 49-69
    Google Scholar
  • 26 Kamath A, Roudenko A, Hecht E. et al. CT/MR LI-RADS 2018: clinical implications and management recommendations. Abdom Radiol (NY) 2019; 44 (04) 1306-1322
    CrossrefPubMedGoogle Scholar
  • 27 van der Pol CB, Lim CS, Sirlin CB. et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology 2019; 156 (04) 976-986
    CrossrefPubMedGoogle Scholar
  • 28 Fowler KJ, Tang A, Santillan C. et al. Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology 2018; 286 (01) 173-185
    CrossrefPubMedGoogle Scholar
  • 29 Yokoo T, Singal AG, Diaz de Leon A. et al. Prevalence and clinical significance of discordant LI-RADS® observations on multiphase contrast-enhanced MRI in patients with cirrhosis. Abdom Radiol (NY) 2020; 45 (01) 177-187
    CrossrefPubMedGoogle Scholar
  • 30 Zhang J, Mavros MN, Cosgrove D. et al. Impact of a single-day multidisciplinary clinic on the management of patients with liver tumours. Curr Oncol 2013; 20 (02) e123-e131
    CrossrefPubMedGoogle Scholar
  • 31 Chang TT, Sawhney R, Monto A. et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB (Oxford) 2008; 10 (06) 405-411
    CrossrefPubMedGoogle Scholar
  • 32 Yopp AC, Mansour JC, Beg MS. et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol 2014; 21 (04) 1287-1295
    CrossrefPubMedGoogle Scholar
  • 33 Serper M, Taddei TH, Mehta R. VOCAL Study Group. et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology 2017; 152 (08) 1954-1964
    CrossrefPubMedGoogle Scholar
  • 34 Sinn DH, Choi GS, Park HC. et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One 2019; 14 (01) e0210730
    CrossrefPubMedGoogle Scholar
  • 35 Charriere B, Muscari F, Maulat C. et al. Outcomes of patients with hepatocellular carcinoma are determined in multidisciplinary team meetings. J Surg Oncol 2017; 115 (03) 330-336
    CrossrefPubMedGoogle Scholar
  • 36 Gashin L, Tapper E, Babalola A. et al. Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. HPB (Oxford) 2014; 16 (11) 1009-1015
    CrossrefPubMedGoogle Scholar
  • 37 Bunnell CA, Weingart SN, Swanson S, Mamon HJ, Shulman LN. Models of multidisciplinary cancer care: physician and patient perceptions in a comprehensive cancer center. J Oncol Pract 2010; 6 (06) 283-288
    CrossrefPubMedGoogle Scholar
  • 38 Van Cleave J, Devine P, Odom-Ball P. Multidisciplinary care of hepatocellular carcinoma. Cancer Pract 1999; 7 (06) 302-308
    CrossrefPubMedGoogle Scholar
  • 39 Cohen GS, Black M. Multidisciplinary management of hepatocellular carcinoma: a model for therapy. J Multidiscip Healthc 2013; 6: 189-195
    Google Scholar
  • 40 Agarwal PD, Phillips P, Hillman L. Multidisciplinary management of hepatocellular carcinoma improves access to therapy and patient survival. J Clin Gastroenterol 2017; 51 (09) 845-849
    CrossrefPubMedGoogle Scholar
  • 41 Duininck G, Lopez-Aguiar AG, Lee RM. et al. Optimizing cancer care for hepatocellular carcinoma at a safety-net hospital: the value of a multidisciplinary disease management team. J Surgical Oncology 2019; 120 (08) 1365-1370
    CrossrefPubMedGoogle Scholar